C02 – terminated

Harnessing molecular vulnerabilities to promote an antitumor immune microenvironment

In C02 G. Herter-Sprie and C. Reinhardt will employ a next generation genetically engineered mouse model to analyze the role of genomic instability on SCLC immunogenicity and thereby immune surveillance, identify whether radiation and chemotherapy influence the sensitivity towards immunological modulation, and characterize the anti-tumor efficacy of PD-1:PD-L1-blocking antibodies, upon prior regulatory T cells (TReg) repression. Ultimately, the findings from this project will help clinicians to design informed patient-tailored clinical studies.

Principal Investigator

Dr. med. Grit S. Herter-Sprie SFB1399
Dr. med. Grit S. Herter-Sprie

Junior Research Group Leader and Medical Resident

University Hospital of Cologne

Department I for Internal Medicine, Hematology/Oncology, Center for Molecular Medicine (CMMC)

Curriculum Vitae (CV)

Univ. Prof. Dr. med. H. Christian Reinhardt SFB1399
Univ. Prof. Dr. med. H. Christian Reinhardt


University Hospital Essen

Department of Hematology and Stem Cell Transplantation

Curriculum Vitae (CV)